Demonstrates increased Good On time in Parkinson’s disease patients, indicating a new treatment option.
To evaluate the impact of CREXONT® (IPX203, ER CD-LD) twice daily (BID) on “Good On” time in Parkinson’s disease patients requiring <500 mg/day immediate-release (IR) carbidopa-levodopa (CD-LD).
No takes yet. Share an insight, caveat, or question.
Allard et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: